离心流式心室辅助装置在儿童中的单中心支持经验
本研究回顾性分析了单中心连续40例(39名)儿童植入离心流式心室辅助装置的结果,中位支持8个月,85%为Interagency Registry for Mechanically Assisted Circulatory Support 1或2级,先天性心脏病患儿较心肌病患儿更小且既往干预更多,心肌病患儿中支持≥3个月者有24%左心室功能正常化。
要点
- 儿童离心流式心室辅助装置支持中位8个月,33%支持≥12个月。
- 先天性心脏病患儿较心肌病患儿更小且既往心脏干预更多。
- 心肌病支持≥3个月者24%左心室功能正常化,4例成功撤除装置。
核心结论
- 儿童离心流式心室辅助装置支持 outcomes 良好,包括先天性心脏病患儿,且心脏恢复发生率增加。
研究设计与样本
- 单中心前瞻性收集的连续病例回顾性分析,纳入年龄≤18岁接受离心流式心室辅助装置支持的39例患者共40次植入。
主要发现
- 中位支持时间8个月(范围1-79),13例(33%)支持≥12个月,累计41患者年。
- 植入时中位年龄11岁(4-18),中位体重35 kg(14-98),中位体表面积1.1 m2(0.7-2.2),16例(40%)体表面积<1.0 m2。
- 先天性心脏病患儿较心肌病患儿显著更小(P < .01)且既往心脏干预更多(P < .01)。
- 心肌病患儿中2例早期死亡(5%);38例成功植入者中36例(95%)出院并门诊管理。
关键数值与推荐
- 总体不良事件率(每100患者月):出血5.1,装置故障0.8,感染6.1,神经功能障碍3.9,肾功能障碍1.0。
- 心肌病支持≥3个月的21例中,5例(24%)左心室功能正常化,4例成功撤除装置,1例仍在支持。
临床怎么用
- 对于儿童心力衰竭患者,离心流式心室辅助装置可作为桥接恢复或移植的策略,尤其心肌病患儿支持≥3个月可能观察至心脏功能恢复。
局限性
- 单中心回顾性设计,样本量较小(39例),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our institutional policy is to continue centrifugal-flow ventricular assist device support for 3 months or more without activation on the transplant wait-list for physical recovery and assessment of possible myocardial recovery. We evaluated our single-institutional outcomes with centrifugal-flow ventricular assist device support in children. METHODS: Prospectively collected outcomes data in consecutive patients aged 18 years or less with centrifugal-flow ventricular assist device support were reviewed. RESULTS: There were 40 implantations in 39 patients (28 with cardiomyopathy, 11 with congenital heart disease, including 3 with univentricular physiology). The median support was 8 months (range, 1-79), with 13 patients (33%) supported for 12 months or more and a cumulative duration of 41 patient-years. The median age and weight at implantation were 11 (4-18) years and 35 (14-98) kg, respectively. The median body surface area was 1.1 (0.7-2.2) m2, with 16 patients (40%) having a body surface area less than 1.0 m2. Thirty-four patients (85%) had Interagency Registry for Mechanically Assisted Circulatory Support 1 or 2. Children with congenital heart disease were significantly smaller (P < .01) and had more prior cardiac interventions (P < .01) than those with cardiomyopathy. There were 2 early mortalities (5%) in children with cardiomyopathy. Of the 38 patients with successful implantations, 36 (95%) were discharged home and managed as outpatients. Overall adverse event rates were 5.1 (bleeding), 0.8 (device malfunction), 6.1 (infection), 3.9 (neurologic dysfunction), and 1.0 (renal dysfunction) (per 100 patient-month). In the 21 patients with cardiomyopathy supported for 3 months or more, 5 (24%) experienced normalization of left ventricular function; 4 underwent successful explantation, and 1 remains on support. CONCLUSIONS: This study demonstrates favorable outcomes of centrifugal-flow ventricular assist device support in children, including those with congenital heart disease, with an increased incidence of cardiac recovery.
引用
- Adachi I, Zea-Vera R, Tunuguntla H, et al. Centrifugal-flow ventricular assist device support in children: A single-center experience. J Thorac Cardiovasc Surg. 2018. PMID: 30770106. doi:10.1016/j.jtcvs.2018.12.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。